FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	Washington	i, D.C. 20549	
<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPRO	OVAL
OMB Number:	3235-0287
Estimated average bure	den
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  O'NEIL PATRICK R.  (Last) (First) (Middle)					<u>IO</u> ]	Issuer Name and Ticker or Trading Symbol     IONIS PHARMACEUTICALS INC     IONS     IONS     IONS     IONS     IONS									(Ch	eck all app Direct X Offic below	licable) tor er (give title v)		10% Ov Other (s below)	vner specify
C/O IONIS PHARMACEUTICALS, INC.  2855 GAZELLE COURT  (Street)  CARLSBAD CA 92010					03/23/2016  4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(Si	tate)	(Zip)			Person														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Da			Date	nsaction th/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Secur Benef Owne	urities eficially ned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
										Code	v	Amount		(A) or (D)	Price		ed ction(s) 3 and 4)	tion(s)		(Instr. 4)
Common Stock (				03/23	3/2016		03/23/2016			M <sup>(1)</sup>		1,000(1	1) A \$		\$10.8	2 10,124			D	
Common Stock 03/				03/23	3/2016	/2016 03/23/2016			S <sup>(1)</sup>		1,000 <sup>(1)</sup> D		D	\$45.	9,124			D		
		-	Гable II -									sed of, onvertik				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	1. Fransa Code (I		1 of   1		Exp	6. Date Exercisal Expiration Date (Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)			8. Price of Derivativ Security (Instr. 5)		es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	te ercisable		Expiration Date	Title		Amount or Number of Shares					
Employee Stock Option (right to	\$10.82	03/23/2016	03/23/2	016	М			1,000	01/0	02/2014 <sup>(2</sup>	2) (	1/01/2020		mmon tock	1,000	\$0	6,10	1	D	

## **Explanation of Responses:**

- 1. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.
- 2. Grant of 1/2/2013 to reporting person of stock options under the Ionis Pharmacueticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 3,925 shares per year. Following this transaction, the option was exercisable as to 2,830 on 3/23/2016.

## Remarks:

/s/Patrick R. O'Neil

03/24/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.